Scott Bowman
Analyst · Simeon Gutman with Morgan Stanley. Please proceed with your question
Good afternoon, everyone, and thank you, Mike. I'll review our fourth quarter and fiscal 2023 performance, and then, provide details about our outlook and assumptions for fiscal 2024. Turning to fourth quarter results. We reported sales of $432 million, a decrease of 9% compared to the fourth quarter of fiscal 2022. Comparable sales decreased 11%. Comparable sales decreased 1% on a two-year stack basis, increased 15% on a three-year stack basis and increased 38% on a four-year stack basis. Non-comparable sales totaled $9 million in the quarter, which was driven by a total of 18 net new stores, including 12 through acquisitions and six net new store openings during fiscal 2023. With respect to trends by consumer group. Comparable sales for residential pool declined 9%, PRO pool declined 13% and residential hot tub declined 23% compared to the prior year period. On a two-year stack basis, comparable sales were flat for residential pool, increased 4% for PRO pool and declined 10% for residential hot tub. These declines were in-line with our expectations and continuation of recent trends in the business. Gross profit was $160 million compared to $217 million in the fourth quarter of fiscal 2022 and gross margin rate declined approximately 860 basis points to 37%. Page 11 of our supplemental deck illustrates our Q4 gross margin rate bridge in more detail. During the quarter, gross margin was impacted by the following factors. First, product gross margin declined 385 basis points in the quarter. This was primarily driven by our June 2023 chemical pricing actions and the negative impact of 70 basis points due to lower rebates. Second, we incurred unexpected incremental inventory adjustment cost that resulted in a 260 basis point headwind in the quarter. This increase was mainly due to excess shrink and scrap due to higher levels of inventory and third-party storage locations, higher movement of goods between facilities and higher levels of unsellable returns. Additionally, gross margin rate was negatively impacted by 120 basis points due to the expensing of capitalized DC cost associated with the drawdown of inventory. And finally, occupancy costs deleveraged by approximately 95 basis points, mainly due to the decline in comparable sales. SG&A was $122 million, down 9% or $12.5 million compared to the fourth quarter of fiscal 2022. Excluding non-recurring items, including costs incurred from the discontinued use of certain software subscriptions and executive transition costs associated with restructuring, SG&A decreased $18 million, driven by lower sales, lower incentive compensation and expense management actions. Adjusted EBITDA was $60 million compared to $100 million in the fourth quarter of fiscal 2022. Interest expense increased to $17 million from $10 million in the fourth quarter of fiscal 2022, due primarily to higher interest rates, and our effective tax rate increased to 22.9% compared to 21.2% in the fourth quarter of fiscal 2022. Adjusted net income was $26 million compared to $64 million in the fourth quarter of fiscal 2022. And adjusted diluted earnings per share was $0.14 compared to $0.35 in the fourth quarter of fiscal 2022. Diluted weighted average shares outstanding were 185 million in both the fourth quarters of fiscal 2023 and fiscal 2022. Moving to our full-year results. Total sales for fiscal 2023 were $1.45 billion, a decrease of 7% compared to the prior year, with comparable sales down 11%. Comparable sales were flat on a two-year stack basis, increased 21% on a three-year stack basis and increased 39% on a four-year stack basis. Non-comparable sales totaled $60 million in fiscal 2023. Gross profit was $548 million for fiscal 2023 compared to $674 million in the prior year and gross margin rate was 37.8%, a decrease of 530 basis points compared to the prior year. As shown on page 11 of the supplemental deck, 205 basis points of the rate decline was due to chemical pricing actions and lower rebates, 215 basis points was due to DC costs and inventory adjustments and 110 basis points was due to occupancy deleverage. SG&A was $446 million for fiscal 2023 compared to $435 million in the prior year. Excluding non-recurring items and non-comp expense from acquisitions and new stores, SG&A decreased $15 million compared to the prior year. Adjusted EBITDA was $168 million for fiscal 2023 compared to $292 million in the prior year. Interest expense was $65 million for 2023 compared to $30 million in the prior year. Adjusted net income was $51 million for fiscal 2023 compared to $176 million in the prior year and adjusted diluted earnings per share was $0.28 for fiscal 2023 compared to $0.95 in the prior year. Moving to the balance sheet. We ended fiscal 2023 with cash and cash equivalents of $55 million compared to $112 million in fiscal 2022. The reduction was primarily due to the decline in net income. At the end of fiscal 2023, we have no balances outstanding on our revolver and availability of $239 million. Year-end inventory was $312 million, a decrease of $50 million or 14% compared to fiscal 2022 and a sequential decrease of $125 million or 29% compared to the third quarter of fiscal 2023. This reduction was possible due to fewer supply chain disruptions, implementation of our new inventory management system and strong execution out of DC locations. Importantly, we are maintaining strong in-stock positions at the store-level to support a high-level of customer service, which is reflecting in our higher NPS scores. At the end of fiscal 2023, we have $790 million outstanding on our secured term loan facility compared to $798 million of fiscal 2022, which translated into a leverage ratio of 4.4 times. The applicable rate on our term loan was SOFR plus 275 basis points in the fourth quarter and our effective interest rate was 8.1% compared to 4.3% in the prior year quarter. Now, for our fiscal 2024 outlook. In fiscal 2024, we expect an uncertain macro-environment and a more cost-conscious consumer especially in discretionary categories to continue affecting sales. We anticipate this to be more acute in the first-half of the year, though we expect positive comps in the back-half of the year due to the lapping of the June 2023 chemical pricing actions and easier compares. With fiscal 2023 being an anomaly from a seasonality standpoint, we are planning for seasonality be more comparable to fiscal 2022 and expect to deliver more than all of our profitability in the second half of the year during our peak pool season. We expect sales of $1.41 billion to $1.47 billion, which assumes normal weather over the course of the year and non-comp sales contribution of approximately [$7 million] (ph). The low-end of our outlook assumes comparable sales growth of approximately negative 3%, while the high-end of our outlook assumes comparable sales growth of approximately 1%. For the full year, we expect to see gross margin rate improvement of approximately 100 basis points compared to the prior year, driven by lower DC costs and fewer inventory adjustments due to reduced inventory levels and improved supply chain efficiencies. That said, we don't expect to see the majority of these benefits until Q4, and we start to lap the unusual items that impacted Q4 fiscal 2023. Additionally, we expect higher impact of deleverage in the first half of the year due to lower sales compared to the prior year. We expect adjusted EBITDA of $170 million to $190 million and expect a slight decline in SG&A expense as we drive efficiency in our cost structure, while making prudent investments in the business. We expect net income of $32 million to $46 million, adjusted net income of $46 million to $60 million and diluted adjusted earnings per share of $0.25 to $0.33. Our outlook assumes an average interest-rate on a floating rate debt of 8.2% and assumes interest expense will be approximately $7 million higher than fiscal 2023. Our outlook also includes an effective tax rate of 26%. We estimate the diluted share count of approximately 185 million shares, which assumes no share repurchases during fiscal 2024. Now, as you'll see on page 14 on our supplemental deck, along with the full-year guidance, we have provided an outlook for Q1. While it has not been our historical practice to provide quarterly guidance, nor do we intend it to be our practice going forward, given the unique dynamics related to Q1 in the comparison to the same period in fiscal 2023, we believe it is appropriate to provide a view of Q1. For the first quarter, we expect total sales of $166 million to $172 million, adjusted EBITDA of negative $27 million to negative $24 million, net income of negative $43 million to negative $41 million, adjusted net income of negative $39 million to negative $37 million and adjusted EPS of negative $0.21 to negative $0.20. Underlying this outlook is our expectation of comp trends will be similar to Q4 of fiscal 2023 and non-comp sales will contribute approximately $3 million. In addition, we expect a significant gross margin decline compared to the prior year quarter, driven by the expansion of capitalized DC costs and occupancy deleverage. Turning to CapEx. We expect to invest $50 million to $55 million in fiscal 2024, of which approximately $20 million is expected to be invested in our existing assets and the remainder is expected to be invested in growth. These investments include new store openings, improving the capacity of our distribution and manufacturing facilities and investing in IT and other projects to improve the business. We also expect a meaningful improvement in working capital and plan to reduce inventories by approximately $50 million. Regarding capital allocation, we expect significant improvement in free cash flow due to higher net income and lower inventory. And our first priority will be to pay-down debt, with the goal of achieving the leverage ratio of 3.5 times to 3.7 times in fiscal 2024. Longer term, our goal is to achieve the leverage ratio of 3.0 times. Our second priority is to invest in growth. This will include organic growth through the opening of 15 new stores and the conversion of six residential stores to the PRO format. We have not included any M&A activity in our fiscal year guidance at this time. The final priority is to return excess cash to shareholders. While we do not expect to repurchase shares in the near term, we will continue to evaluate this based on our financial position and market conditions. Before I turn it back to Mike, I want to address two items that will be covered in greater detail in our Form 10-K. In short, we have identified two material weaknesses in internal controls over financial report. One weakness relates to insufficient controls over an internal database that is used to calculate vendor rebates. And the other weakness related to controls over the performance of fiscal inventories. As a result, we are designing and implementing new processing and enhanced control to address the underlying causes of the material weaknesses and expect remediation to be completed during fiscal 2024. And with that, I will hand it back over to Mike. Thank you.